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It has become apparent that gut microbiota is closely associated with cardiometabolic
diseases (CMDs), and alteration in microbiome compositions is also linked to the host
environment. Next generation sequencing (NGS) has facilitated in-depth studies on
the effects of herbal medicine and functional food on gut microbiota. Both herbal
medicine and functional food contain fiber, polyphenols and polysaccharides, exerting
prebiotics-like activities in the prevention and treatment of CMDs. The administrations
of herbal medicine and functional food lead to increased the abundance of phylum
Bacteroidetes, and genus Akkermansia, Bifidobacteria, Lactobacillus, Bacteroides and
Prevotella, while reducing phylum Firmicutes and Firmicutes/Bacteroidetes ratio in gut.
Both herbal medicine and functional food interact with gut microbiome and alter the
microbial metabolites including short-chain fatty acids (SCFAs), bile acids (BAs) and
lipopolysaccharides (LPS), which are now correlated with metabolic diseases such as
type 2 diabetes (T2D), obesity and non-alcoholic fatty liver disease (NAFLD). In addition,
trimethylamine (TMA)-N-oxide (TMAO) is recently linked to atherosclerosis (AS) and
cardiovascular disease (CVD) risks. Moreover, gut-organs axesmay serve as the potential
strategy for treating CMDs with the intervention of herbal medicine and functional
food. In summary, a balance between herbal medicine and functional food rich in fiber,
polyphenols and polysaccharides plays a vital role in modulating gut microbiota (phylum
Bacteroidetes, Firmicutes and Firmicutes/Bacteroidetes ratio, and genus Akkermansia,
Bifidobacteria, Lactobacillus, Bacteroides and Prevotella) through SCFAs, BAs, LPS
and TMAO signaling regarding CMDs. Targeting gut-organs axes may serve as a new
therapeutic strategy for CMDs by herbal medicine and functional food in the future. This
review aims to summarize the balance between herbal medicine and functional food
utilized for the prevention and treatment of CMDs through modulating gut microbiota.
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INTRODUCTION
The Human Microbiome Project funded by National Institutes
of Health (NIH) (Qin et al., 2010) and Metagenomics of the
Human Intestinal Tract (MetaHIT) consortium funded by
European Commission (Turnbaugh et al., 2007) have promoted
better understanding of the functional properties and healthy
composition of gut microbiota. Various microbial communities
and their genes (the microbiome) are present in human body,
influencing human health and diseases (Human Microbiome
Project, 2012). The human gut microbiota contains a diverse
array of microorganisms, including bacteria, archaea and fungi
that colonize the surfaces of the gastrointestinal (GI) tract;
bacteriophage are also in high abundance in GI tract (Savage,
1977). Six bacterial phyla dominate the gut microbiota of
healthy adult subjects: Firmicutes, Proteobacteria, Bacteroidetes,
Fusobacteria, Actinobacteria, and Verrucomicrobia. The
intestine hosts >1014 microorganisms with critical physiological
roles, and the microbial compositions differ along the digestive
tract (Aron-Wisnewsky and Clement, 2016). The large intestine,
particularly the colon, harbors a complex and dynamic microbial
ecosystem with high densities of living bacteria. These bacteria
achieve concentrations of approximately 1011–1012 cells/g of
luminal contents (Simon and Gorbach, 1984; Guarner and
Malagelada, 2003).
A multitude of literature supports the role of gut microbiota
in the development and progression of cardiometabolic diseases
(CMDs). CMDs have become a worldwide epidemic, with
dramatically increasing prevalence of cardiovascular disease
(CVD), obesity, type 2 diabetes (T2D), non-alcoholic fatty
liver disease (NAFLD), atherosclerosis (AS), hypertension,
and dyslipidemia (Hansen et al., 2015; Aron-Wisnewsky and
Clement, 2016; Meyer and Bennett, 2016; Woting and Blaut,
2016; Micha et al., 2017). In the search for novel therapeutic
leads, the association of gutmicrobiota andmicrobial metabolites
with the development of CMDs holds the potential in future drug
discovery (Koopen et al., 2016).
Disruption of microbial ecosystems during crucial
developmental periods could affect body physiology or
cause undesired negative effects. For instance, the overuse
of antibiotics in early life is associated with obesity in both
humans and rodents (Cho et al., 2012). Herbal medicine such
as traditional Chinese medicine (TCM) can be used as an
alternative strategy to modulate microbiota and for modern drug
discovery. Moreover, certain food components provided benefits
beyond basic nutrition, leading to the concept of functional
Abbreviations: CMDs, Cardiometabolic diseases; CVD, cardiovascular disease;
T2D, type 2 diabetes; NAFLD, non-alcoholic fatty liver disease; AS, atherosclerosis;
CKD, chronic kidney disease; MI, myocardial infarction; SCFAs, short-chain
fatty acids; Bas, bile acids; LPS, lipopolysaccharide; TMAO, trimethylamine–
N-oxide; TCM, traditional Chinese medicine; MetaHIT, Metagenomics of the
Human Intestinal Tract; GI, gastrointestinal; HFD, high-fat-diet; UC, ulcerative
colitis; AMR, antimicrobial resistance; RSV, resveratrol; GQD, GegenQinlian
Decoction; FMO3, flavin-containing monooxygenase 3; GLP-1, glucagon-like
peptide-1; MCP1, monocyte chemoattractant protein 1; ZO-1, zona occludens-
1; FXR, farnesoid X receptor; FGF15, fibroblast growth factor 15; Fiaf, fasting-
induced adipose factor; TLR4, toll-like receptor 4; GPAT1, glycerol-3-phosphate
acyltransferase 1.
food and nutraceuticals. Functional food offer benefits beyond
basic nutrition when consumed regularly as part of a diet.
Herbal medicine and functional food produce a large diversity of
secondary metabolites which display a broad array of biological
and pharmacological properties (Wink, 2015) and are widely
accepted as high-efficiency and low toxicity “medicinal diets”
which are capable of avoiding certain side-effects. In this review
article, recently discovered mechanisms of herbal medicine
and functional food are summarized and their contributions
to prevention and treatment of CMDs through modulating
microbiota are also outlined.
GUT MICROBIOTA IN CMDS
Gut Microbiota in Cardiovascular Diseases
In recent years, an increasing number of reseachers begin to
pay their attention to the mutual effects on intestinal flora
and CVDs, resulting from the new findings of gut microbe–
derived metabolite trimethylamine (TMA)-N-oxide (TMAO).
Gut microbiota has an intimate relationship with CVDs,
including thrombosis, AS, myocardial infarction (MI) and stroke.
TMAO
TMAO was first identified as a contributor to CVD in a large
clinical cohort of 1,876 subjects by Stanley L. Hazen team using
an untargeted metabolomics platform (Wang et al., 2011). In
a subsequent expansion study of 4,007 subjects undergoing
elective coronary angiography indicated an association between
elevated TMAO levels in plasma and increased risk for major
adverse cardiovascular events (MACE) over a 3-year period in
humans (Tang et al., 2013). Then, increasing clinical reports
support an involvement of plasma TMAO levels in the etiology
of various CVDs. For example, elevated plasma TMAO levels in
patients predict a high atherosclerotic burden (Senthong et al.,
2016a), long-term adverse event risk and incremental prognostic
of peripheral artery disease (PAD) (Senthong et al., 2016b),
higher long-termmortality risk of coronary artery disease (CAD)
(Senthong et al., 2016c), and adverse clinical outcomes in heart
failure (HF) (Tang et al., 2014, 2015b; Troseid et al., 2015). Higher
TMAO levels provide clinical utility in risk stratification of acute
coronary syndromes (ACS) (Li X. S. et al., 2017) showing a direct
pro-thrombotic effect (Zhu et al., 2017), predict close association
with poor prognosis of MI (Suzuki et al., 2017). A systematic
review and meta-analysis reconfirmed elevated concentrations
of TMAO and its precursor TMA were associated with
increased risks of MACE (Heianza et al., 2017). Furthermore,
gut microbiota played an obligatory role in the metabolism
of TMA, eight species (Anaerococcus hydrogenalis, Clostridium
asparagiforme, Clostridium hathewayi, Clostridium sporogenes,
Escherichia fergusonii, Proteus penneri, Providenciarett geri,
and Edwardsiella tarda) in two different phyla (Firmicutes
and Proteobacteria) and six genera correlated with choline
consumption and TMA accumulation were identified (Romano
et al., 2015). Undoubtedly, TMAO had become a new biomarker
in diagnosis of CVD.
The conclusions of cumulative reports on the meta-
organismal metabolic pathway for TMAO production and
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its possible mechanisms resulting in CVD are highlighted:
¬TMA production: phosphatidylcholine (PC), choline, and L-
carnitine, generating the precursor TMA by gut microbiota
cleavage, were abundant in dietary foods such as red meat,
shellfish, egg yolk and high-fat dairy products (Wang et al.,
2011). Until now, either choline or L-carnitine as substrate,
TMA is produced by two identified distinct microbial enzyme
systems. Catalytic unit (cutC) and a regulatory polypeptide
(cutD) are required for TMA production from choline (Craciun
and Balskus, 2012; Craciun et al., 2014). The catalytic protein
(CntA) and the regulatory protein (CntB) are involved in
TMA production form L-carnitine (Zhu et al., 2014). ­TMA→
TMAO: hepatic flavin monooxygenase 3 (FMO3) expression
was up-regulated by bile acids (BAs) via nuclear receptor
farnesoid X receptor (FXR) activation (Bennett et al., 2013).
TMA was readily absorbed and traveled through the portal
circulation to the liver and was oxidized into TMAO by FMO3
(Wang et al., 2011; Bennett et al., 2013). ®TMAO induced
or enhanced cell phenotypic changes: elevated plasma TMAO
induced endothelial dysfunction via activating reactive oxygen
species (ROS)/thioredoxin-interactive protein (TXNIP)/nod-
likereceptor family pyrin domain containing 3 (NLRP3)
inflammasome (Sun X. et al., 2016) and impairing endothelial
nitric oxide synthase (eNOS)-derived NO bioavailability (Hu
et al., 2015; Li T. et al., 2017). In addition, TMAO accelerated
vascular inflammation through mitogen-activated protein kinase
(MAPK) and nuclear factor-κB (NF-κB) signaling (Seldin
et al., 2016), reduced endothelial self-repair, and increased
monocyte adhesion partly via the pathway of protein kinase
C (PKC)/NF-κB/vascular cell adhesion molecule-1 (VCAM-1)
activation (Ma et al., 2017). Moreover, TMAO contributed to
macrophage cholesterol accumulation and foam cell formation
(Wang et al., 2011). Furthermore, TMAO elevated platelet
hyperreactivity, enhancing agonists-induced platelet activation
through intracellular Ca2+ mobilization (Zhu et al., 2016).
These changes in cell phenotype contribute to atherosclerotic
CVD. ¯TMAO promoted CAD in animal studies: TMAO
accelerated AS by reversing cholesterol transport and altering
bile acids (BAs) composition (Koeth et al., 2013), enhanced
thrombosis formation by activating platelet (Zhu et al.,
2016), exacerbated pressure overload–induced heart failure by
inducting adverse cardiac remodeling (Organ et al., 2016).
Attention should be paid to the gender identity in the study
of TMAO synthesis, since FMO3 expression is higher in
females than males in both human and mouse (Bennett et al.,
2013).
For further research, pharmacologic inhibition of TMAO
producition will be a potential therapeutic strategy to reduce
CVD events by targeting microbial community, microbial
enzyme and/or FMO3 expression. The mechanisms of TMAO
pathway (PC, choline, L-carnitine→TMA→FMO3→TMAO)
linking the specific microbiota to cardiovascular functionis
are very important and need to be further elucidated. In
addition to the new finding of TMAO, other microbial
metobolites such as SCFAs (Marques et al., 2017), BAs
(Mayerhofer et al., 2017), and LPS (Pastori et al., 2017)
which are beneficial for CVD will not be discussed in details
here.
Gut Microbiota in Metabolic Diseases
A considerable number of publications have reported
correlations between gut microbiota and metabolic diseases
(Moreno-Indias et al., 2014; Janssen and Kersten, 2015;
Greenhill, 2016; Saad et al., 2016; Sonnenburg and Backhed,
2016; Woting and Blaut, 2016). Specific metabolic abnormalities
such as pro-inflammatory states, insulin resistance, glucose
intolerance, dyslipidemia, high blood pressure and NAFLD,
which accompanies gut microbiota dysbiosis, often develop
in obese people. Moreover, obesity and T2D are considered
as a medical condition, which not only contributes to the risk
of developing CVD and cancer, but also negatively affects
longevity and quality of life. Here, we describe several crucial
mechanisms (mainly about SCFAs, LPS and BAs) that contribute
to understanding the correlation between gut microbiota and
obestiy/T2D.
SCFAs
The intestinal microbial fermentation and degradation of dietary
nondigestible fiber and polysaccharides to SCFAs (acetate,
propionate and butyrate) are regarded as potential metabolic
targets to prevent obesity/T2D in glucose metabolism and insulin
resistance. Besides, several mechanisms correlate with SCFAs
affect body weight via energy intake and energy harvesting, and
link with insulin sensitivity through inflammatory resoponse,
lipid storage and adipose tissue function (Canfora et al.,
2015). SCFAs, serving as energy substrates, directly inhibit
histone deacetylases (HDACs) and activate G-protein-coupled
recepotors (GPCRs). Moreover, butyrate also has effect on
epithelial barrier function by increasing mucus production and
protein zonula occludens-1 (ZO)-1, occludin expression (Bordin
et al., 2004; Peng et al., 2007). GPR41and GPR43 targets are
of significance for SCFAs. Gut microbiota promotes adiposity
and body weight via SCFAs receptor GPR41. The expression
of peptide YY (or PYY), a key hormone involved in the
elevation of intestinal transit rate and reduction in energy
hearvest, is decreased in GPR41−/− mice (Samuel et al., 2008).
On the contrary, SCFAs may prevent obesity via activation
of GPR43. Normal diet GPR43−/− mice are obese, whereas
HFD-fed GPR43+/+ mice remain lean. Insulin signaling in
adipocytes and fat accumulation in white adipose tissue (WAT)
are inhibited via acetate-medatied GPR43 (Kimura et al., 2013).
These distinct differences remain to be analyzed in how the
gut microbiota is modulated. Besides, GPCR43 activation by
SCFAs promotes the release of glucagon-like peptide-1 (GPL-1)
by intestinal enteroendocrine L cells, thereby leading to insulin
release and stimulating glucose tolerance (Tolhurst et al., 2012).
Furthermore, a recent paper reported that acetate contributes
to GPR43-mediated intestinal IgA response to microbiota,
leading to crucial role in intestinal homeostasis maintenance and
intestines inflammation denfence (Wu et al., 2016). Apparently,
SCFAs-mediatedGPCRs signaling inmice shows extensive effects
on obesity/T2D, but the role of GPR41/43 signaling in humans
remains to be established.
LPS
Endotoxin LPS is a major component of the gram-negative
bacterial (such as Escherichia coli) outer membrane.
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HFD-induced gut microbiota dysbiosis can alter gut permeability
and then increase cirlulating LPS levels which promotes low-
grade inflammation and insulin resistance and, ultimately,
obesity and T2D in rodents and humans (Cani et al., 2007, 2008;
Creely et al., 2007). In addition, Increased intestinal epithelial
barrier permeability is due to increased endocannabinoid system
tone (Muccioli et al., 2010) and tight junctions (ZO)-1, occludin
and claudin-1 expression (Wang J. H. et al., 2014). LPS stimulates
inflammatory response mainly by binding to CD14/Toll-like
receptor 4 (TLR4) which is respnsible for the recruitment and
activation of MyD88 adaptor and NF-κB transcription factor,
inducing the pro-inflammatory factors interleukin-6 (IL-6),
interleukin-1β (IL-1β) and monocyte chemoattractant protein-1
(MCP-1) secretion (Hennessy et al., 2010), and therefore it
triggers matabolic diseases (Robbins et al., 2014; Kang et al.,
2016). Metabolic characteristics of obesity and T2D in mice
were not initiated by injecting LPS when CD14/TLR4 receptor
was genetically deleted, showing the significant contribution of
LPS/CD14/TLR4 signaling (Shi et al., 2006; Cani et al., 2007,
2008; Poggi et al., 2007). Unexpectedly, insulin is more sensitive
in TLR4−/− (Shi et al., 2006) mice, but less in TLR6−/− (Vijay-
Kumar et al., 2010) mice with the modulator of gut microbiota
than wild-type controls.
BAs
BAs is produced in the liver from cholesterol and metabolized in
the gut by the intestinal microbiota (Midtvedt, 1974). Inversely,
BAs can modulate gut microbial composition via innate immune
genes activation in the small intestine (Wahlstrom et al., 2016).
Cholic acid (CA) and chenodeoxycholic acid (CDCA) are the
primary BAs produced in humans, whereas CA and muricholic
acids (MCAs) are generated in rodents. Besides, mice also
produce ursodeoxycholic acid (UDCA) as primary BAs (Sayin
et al., 2013), whereas as a secondary BA in human (Ishizaki
et al., 2005). The primary BAs are converted into secondary BAs
by gut microbial modifications. BAs play multiple roles in the
control of obesity/T2D related glucose and lipid metabolism,
and energy homeostasis by activating the nuclear FXR and the
cytoplasmic G protein-coupled membrane receptor 5 (TGR5)
which regulate a large number metabolic pathways in the host
(Thomas et al., 2008, 2009; Wahlstrom et al., 2016). On one
hand, FXR is activated mainly by the CA and CDCA (Makishima
et al., 1999; Parks et al., 1999; Wang et al., 1999), while TGR5
is stimulated mostly by LCA and DCA which are secondary
BAs metabolized from CA and CDCA (Maruyama et al., 2002;
Chen X. et al., 2011). On another, Tα/βMCA (primary BAs in
mice) and UDCA inhibit FXR activation (Li et al., 2013; Sayin
et al., 2013; Mueller et al., 2015). Furthermore, GLP-1 synthesis
is inhibited by FXR activition (Trabelsi et al., 2015), while it
is activated and secreted by TGR5 activation in colonic L cells
(Thomas et al., 2009). GLP-1 signaling may be exploited into a
new therapy for T2D with the help of gut microbiota (Claus,
2017; Grasset et al., 2017). Hepatic cholesterol 7a-hydroxylase
(CYP7A1) is regulated by intestinal FXR with the contribution
of a fibroblast growth factor15 (FGF15) activity (Inagaki et al.,
2005). What’s more, recent study showed HFD-fed FXR−/− mice
an obesity phenotype compared to the wild-type mice (Parséus
et al., 2016). Thus, targeting BAs, FXR, and/or TGR5 signaling
with microbiota, may shed a new light on preventing or treating
metabolic diseases. At present, our knowledge on the mutual
effects between BAs and gut microbiota is still far from complete.
In recent studies, the gut metabolite TMAO is also found
to have an intimate relationship with metabolic diseases such
as T2D (Dambrova et al., 2016; Tang et al., 2016; Schugar
et al., 2017), NAFLD (Chen Y. M. et al., 2016), chronic kidney
disease (CKD) (Tang et al., 2015a; Xu K. Y. et al., 2017)
and bariatric surgery (Troseid et al., 2016), along with the
metabolic functions including insulin resistance (Oellgaard et al.,
2017) and BAs metabolism (Wilson et al., 2016). With the
rapid development in the field of intestinal microbiota, the gut
metabolites like TMAO, SCFAs, LPS, and BAswith their signaling
interplay betweenmicrobiota, have evolved as promising avenues
for prevention and treatment of CMDs. Herbal medicine and
functionl food with the properity of muti-ingredient, muti-
target and muti-pathway action may serve as a prebiotic-like
remediation (Laparra and Sanz, 2010; Xu J. et al., 2017). How
might they work in CMDs by modulating gut microbiota are
discussed below.
HERBAL MEDICINE AND GUT
MICROBIOTA
The effectiveness of antibiotics in modern medicine has
diminished somewhat due to the development of multi-drug
resistant bacteria after using for more than 70 years. New
classes of antimicrobial drugs are unlikely to become widely
available any time soon (Laxminarayan et al., 2016). If and
when they do, bacteria, viruses and other microbes will again
evolve antimicrobial resistance (AMR) through variety of ways
including horizontal gene transfer of mobile genetic elements
(Carroll et al., 2014; Jorgensen et al., 2016). Experimental
evidence, particularly rodent studies, showed convincingly that
prebiotics, non-digestible, fermentable carbohydrates and fibers
are capable of enhancing the growth of specific beneficial gut
bacteria, thus reducing body weight, reversing insulin resistance
and exerting anti-inflammatory effects (Bindels et al., 2015;
Sonnenburg and Backhed, 2016). However, these effects have
yet to be confirmed by intervention studies in human. Recent
investigations support the idea of the involvement of intestinal
bacteria in host metabolism and preventative therapeutic
potential of prebiotic interventions for CMDs. Herbal medicine
may therefore serve as a potential prebiotic remedy to treat
CMDs and complications.
Several herbal medicine formulae, herbals and nutraceuticals
that contain fiber, polyphenol, polysaccharide and certain other
substances have anti-obese, anti-diabetic and anti-atherosclerotic
effects through the modulation of diverse gut microbiota. These
herbals with their components have the potential to be a new
source for CMD drugs discovery that target specifically the
gut microbiota, as summarized in Tables 1–3. According to the
early direct evidence in 187 T2D patients, a herbal formula
Gegen Qinlian Decoction (GQD) including four herbs: Gegen
(Radix Puerariae), Huangqin (Radix Scutellariae), Huanglian
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(RhizomaCoptidis) and Gancao (Honey-fried Licorice Root),
showed the anti-T2D effect partly by enriching the amounts of
specific beneficial bacteria Faecalibacterium spp. (Xu et al., 2015).
Interestingly, both Rhizoma coptidis (as the major component of
GQD) and berberine (as the main phytochemicals of Rhizoma
coptidis) are confimed to have an anti-obese effect by inhibiting
the ratio of Firmicutes/Bacteroidetes, and lowering the growth
of Lactobacillus (a classical type of Firmicutes) in HFD-fed mice
feces. In addition, Rhizoma coptidis and berberine can reduce
HFD-induced body and visecral adipose weights, and blood
glucose and lipid levels in mice (Xie et al., 2011).What’s more,
berberine increases putative SCFA-producing bacteria, including
Blautia, Allobaculum, Bacteriodes, Blautia, Butyricoccus, and
Phascolarctobacterium, possibly leading to anti-obese and anti-
diabetic effects in the host (Zhang et al., 2012a, 2015).
Rhizoma coptidis and berberine, also the main ingredients of
GQD, may contribute to the significant resistance to metabolic
disease by targeting intestinal microbiota, which need to be
further confirmed in clinical trials. A recent study showed that
berberine improved non-alcoholic steatohepatitis (NASH) by
restoring Biffidobacteria and reducing Firmicutes/Bacteroidetes
ratio (Cao et al., 2016). Another herbal formula Qushi
Huayu Decoction (QHD), a mixture of five herbs (Artemisia
capillaries Thunb, Gardenia jasminoides Ellis, Fallopia japonica,
Curcuma longa L., and Hypericum japonicum Thunb.) and
two active ingredients (geniposide and chlorogenic acid)
reduces oxidative stress and inflammatory response in liver
by inducing glutathione-generating enzymes, decreases lipid
synthesis and elevates steatosis by inhibiting glucokinase
expression, and ameliorates gut barrier function and alleviates
liver inflammation by inducing Treg-producing baceria. In these
studies, 12 phyla of gut bacteria were altered, including increased
Fusobacteria, Lentisphaerae, Verrucomicrobia, Cyanobacteria,
Deferribacteres, Proteobacteria, and Bacteroidetes, as well as
decreased Firmicutes, Tenericutes and Actinobacteria (Yang
et al., 2017).
Resveratrol (RSV), a natural polyphenolic compound extrated
from herbal medicine Rhixoma Polygoni Cuspidati or functional
food peanut, grape, and Fructus Mori, exerts antioxidant, anti-
inflammatory (Walker et al., 2014), anti-tumor, cardioprotective,
aging-delay, and anti-obesity effects (Baur and Sinclair, 2006;
Zhang et al., 2012b). On one hand, RSV decreases TMAO levels
and increases hepatic BA neosynthesis via increasing the genera
Lactobacillus and Bifidobacterium, thus attenuating TMAO-
induced AS in ApoE−/− mice. RSV-induced BA neosynthesis
was partially mediated through the enterohepatic FXR-fibroblast
growth factor 15 (FGF15) axis (Chen M. L. et al., 2016). On
another, RSV increases the ratio of Bacteroidetes/Firmicutes
and the growth of Lactobacillus and Bifidobacterium. It also
reduces the growth of Enterococcus faecalis through fasting-
induced adipose factor (Fiaf, a key gene expresses in the
intestine and negatievely regulated by interstinal flora) signaling,
decelerating the development of obesity (Qiao et al., 2014).
RSV is probably an unique and firstly reported natural
product that mediates protection against both CVD and
metabolic diseases via gut microbiota to date. In addition,
quercetin, a key member of the polyphenol family, is discovered
in numerous medicinal botanicals, including Ginkgo biloba,
Hypericum perforatum, and Sambucus canadensi and also
found in a variety of functional foods including apple, grape,
berry, onion and tea (Li Y. et al., 2016). Intake of quercetin
reduced body weight gain and attenuated serum insulin levels
by reducing Firmicutes/Bacteroidetes ratio and inhibiting the
growth of bacterial species Erysipelotrichaceae, Bacillus and
Eubacterium cylindroides, which correlated with HFD-induced
obesity (Etxeberria et al., 2015a). Moreover, it was shown in a
recent study that curcumin, the major polyphenolic ingredient
of an edible herb Curcuma longa L. improved intestinal
barrier function by modulation of intracellular signaling, and
organization of tight junctions, providing a mechanism that
curcumin modulates chronic inflammatory diseases despite
poor bioavailability (Wang J. et al., 2017). The details of
some other herbal medicines, including formulae, herbals and
phytochemicals reportedly to achieve their therapeutic effects for
CMDs through gut microbiota modulation are summarized in
Tables 1–3.
FUNCTIONAL FOOD AND MICROBIOTA
Functional food has the advantages of wide availability,
ease of preparation and fewer adverse effects. They could
be well suited for CMDs remedies due to their potential
effects such as anti-inflammatory, antioxidants, antiestrogenics,
immunomodulatory, whereas purified active compounds are
preferable as pharmaceutical drugs for the treatment of severe
chronic symptoms (Martel et al., 2016; Meyer and Bennett, 2016).
Epidemiological studies have identified associations between
frequent consumption of fruits, vegetables, whole grains and
teas, which are rich in fiber, polyphenol, and polysaccharide
could reduce the risk of CMDs (Woodside et al., 2013; Klinder
et al., 2016). These phytochemicals and their metabolic products
may inhibit pathogenic bacteria while stimulating the growth of
beneficial bacteria for CMDs (Laparra and Sanz, 2010).
Apples are among the most frequently consumed fruits
to prevent obestiy by modulating gut microbiota with their
multiple components, including fiber, pectin (Jiang et al., 2016),
procyanidins (Masumoto et al., 2016) and polysaccharides (Wang
S. et al., 2017). Administration with apple procyanidins (a
subclass of polyphenols) for 20 weeks was able to reduce
obesity, decrease lipid metabolism related genes expression,
lower LPS levels and gut permeabiliby through decreasing
the Firmicutes/Bacteroidetes ratio and increasing Akkermansia
proportion (Masumoto et al., 2016). In addition, treatment
with apple polysaccharide inhibited chronic inflammation, gut
permeability, and SCFAs production, leading to lower abundance
of Firmicutes and Fusobacteium, and higher Bacteroidetes
and Lactobacillus in HFD-fed rats (Wang S. et al., 2017).
Furthermore, the reciprocity between apple ingredients and
the gut microbioa may benefit cardiovascular health (Koutsos
et al., 2015). Unexpectedly, diet apple fiber and flavone were
positively associated with Blautia, Lactobacillus, Bifidobacterium,
and Faecalibacterium, showing great significance for the patients
who suffer from systemic lupus erythematosus (SLE) (Cuervo
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et al., 2015; Table 4). As another example, ingestion of laminarin,
a kind of polysaccharides extracted from Laminaria japonica,
by HFD-fed mice significantly increased genus Bacteroides and
decreased Firmicutes, with elevated energy metabolism (Nguyen
et al., 2016;Table 5). Besides, 3,3-dimethyl-1-butanol (DMB), the
structural analog of choline detected in some functional food
such as balsamic vinegars, red wines, and olive oils (Kitai and
Tang, 2017), is an inhibitor of TMA formation through inhibition
of microbial TMA lyases. Therefore, it inhibited choline diet-
promoted macrophage foam cell formation and atherosclerotic
lesion development without altering the circulating cholesterol
levels (Wang Z. et al., 2015).
Moreover, vegetables (e.g., bamboo shoot), whole grains (e.g.,
wheat, barley and oat), and teas (e.g., green tea, oolong tea, black
tea and fuzhuan tea), exert positive effects on CMDs through
modulating gut microbiota (Table 4). Numerous instances are
detailed in Tables 4, 5. Although, intervention studies conducted
both in animals and humans have demonstrated beneficial effects
of functonal foods on anti-inflammation, vascular function, and
energy metabolism, the apparent association with altered gut
microbiota is still lacking.
OVERLAPING EFFECTS BETWEEN
HERBAL MEDICINE AND FUNCTIONAL
FOOD ON GUT MICROBIOTA
Medicine and food deriving from the same source has been
realized since ancient times. In TCM, food is conceptualized
according to both nutritional and functional aspects, and can
be used to treat illnesses. The “medicine-food homology”
concept has given a new meaning since the discovery of
human-microbiota existing as a whole symbiotic ecosystem.
Interestingly, a series of overlapping characteristics through
modulating gut microbiota for CMDs between herbal medicine
and functional food are uncovered based on the description
above (Tables 1–5): Àshared components, Ásimilar functions,
Âcommon mechanisms, and Ãsame intestinal microbiota.
First and foremost, there is no absolute boundary between
medicine and food. Some medicines are food whereas certain
foods can be employed as medicine. Lonicera japonica Thunb,
Cassia obtusifolia L., Semen Coicis, adlay, Zingiber officinale
Roscoe (major ingredient: curcumin), and mulberry (main
ingredient: RSV), are edible medicines, there are only dosage
differences between edible and medicinal use. These herbs
not only belong to medicine with valid efficacies for CMDs
remedy, but also are delicious food with rich nutrients. Besides,
some medicines have been developed into nutraceuticals, which
contain important natural bioactive compounds that confer
health-promoting and medical benefits to humans, such as
Ganoderma lucidum, Herba Epimdii, Ophiopogon japonicas,
Rehmannia glutinosa Libosch, Rheum rhabarbarum (major
ingredient: rhein), and lingonberry, seeTables 1–3. Furthermore,
many foods could serve as nutraceutical candidates, and some
of those, such as pomegranate peel, bamboo shoot, grape (major
ingredient: RSV), and laminarin have the potential to branch into
medicines (Tables 4, 5).
Secondly, the components of fibers (e.g., bamboo shoot, nopal,
and yellow pea), polyphenols (e.g., GQD, Flos Lonicera, adlay,
apple, grape, orange, nopal and tea) and/or polysaccharides
(e.g., Ginseng decoction, Yupingfeng, Ganoderma lucidum,
Polygonatum kingianum, Ophiopogon japonicas, apple and
barley) are shared in most herbals and foods, exerting prebiotics-
like effects for CMDs, which can be seen inTables 1–5. Moreover,
polyphenol phytochemicals such as RSV and quercetin are
present in both herbals and foods. These components are
able to escape absorption in the upper gastrointestinal tract
and reach the large intestine without breaking down. Thus,
these components can also be converted by local microbiota
to biologically active and bioavailable metabolites with systemic
effects.
Thirdly, just as what we have introduced above, gut
microbiota-derived metabolites such as SCFAs, LPS, Bas, and
TMAO are the most likely microbial metabolites linking CMDs
remedy to intestinal microbiota. Numerous herbals and foods
are likely to prevent and treat CMDs through these mediators.
Improved gut permeability and gut integrity in conjunction
with the increased expression of ZO-1 and/or occludin-1 and/or
claudin-1, resulted in reduction of circulating LPS levels and a
series of inflammatory response, which are affected by herbals
(Yupingfeng polysaccharides enhanced immunity, Sun H. et al.,
2016). QHD was used in the treatment of NAFLD (Feng
et al., 2017); Flos Lonicera ameliorated obesity (Wang J. H.
et al., 2014); curcumin attenuated AS (Ghosh et al., 2014) and
foods [apple derived polyphenols and polysaccharide prevented
obesity, (Masumoto et al., 2016; Wang S. et al., 2017), nopal and
capsaicin were used in combacting obesity (Kang et al., 2017;
Sanchez-Tapia et al., 2017)]. SCFAs production was shown to
restore aberrant levels of gut hormones such as GLP-1, PYY, and
the activation of GPR43. SCFAs production are also promoted
by berberine in energy metabolism, insulin resistance and obesity
(Xie et al., 2011; Zhang et al., 2015; Xu J. H. et al., 2017); elevated
by apple polysaccharide in chronic inflammation, and enriched
by oat in obesity treatment (Wang S. et al., 2017). In addition,
Polygonatum kingianum and taurine intervene with both SCFAs
and LPS levels in different CMDs (Yu et al., 2016; Yan et al., 2017).
TMAO levels were inhibited via the reduction of TMA formation
by RSV and then attenuate AS (Wang Z. et al., 2015; Chen M. L.
et al., 2016). At the same time, RSV increased BAs deconjugation
and fecal excretion by enhancing the activity of hydrolase activity,
which displayed correlation with the lowered BA content in
ilealby suppressing FXR-FGF15 axis and promoting CYP7A1
expression (ChenM. L. et al., 2016). All of these interventions are
along with the changed microbiota composition. An increasing
number of metabolic pathway and potential mechanisms are
studied on the mediators of SCFAs, LPS, BAs and TMAO. These
studies provide a better understanding of how herbals and foods
prevent or treat CMDs by gut microbiota. The cross-talk between
these mediators and specific alteration of intestinal bacteria in
host physiology, as well as the precise contributing elements in
herbals and foods for CMDs remedy shoud be subjects for future
studies.
Finally, previous work has established that generaClostridium,
Lactobacillus and Ruminococcus, as well as the butyrate producers
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TABLE 5 | Functional food phytochemicals and gut microbiota.
Phytochemicals Category Objects Diseases Physiological function related to
gut microbiota
Gut microbiota References













Reduce inflammatory response and







Shang et al., 2016
Melatonine Alkaloid C57BL/6J
mice





Xu P. et al., 2017
Fructans Polysaccharide C57BL/6J
mice












Obesity ÀPrevent HFD-induced gut barrier
dysfunction by inhibiting














AS Reduce microbial trimethylamine
formation and inhibit choline
diet-enhanced AS.
N/A Wang Q. et al.,
2015
Eubacterium, Fecalibacterium and Roseburia are the important
members of Firmicutes. Bacteroidetes including the genus
Bacteroides, Prevotella and Xylanibacter are known to be efficient
degraders of dietary fiber (Simpson and Campbell, 2015).
Genus Bifidobacterium is a major member of Actinobacteria.
Proteobacteria contains Escherichia and Desulfovibrio, whereas
Verrucomicrobia includes only the mucus-degrading genus
Akkermansia so far (Schroeder and Backhed, 2016). Tables 1–5
show that the ratio of Firmicutes/Bacteroidetes is modulated
in most herbal- and food-intervention studies for CVD as
well as various metabolic diseases. For example, decreased
ratio of Firmicutes/Bacteroidetes was observed in obesity after
intervened by herbals [Daesiho-tang (Hussain et al., 2016),
Ganoderma lucidum (Chang C. J. et al., 2015), Flos Lonicera
(Wang J. H. et al., 2014), Rhizoma coptidis (Xie et al., 2011),
Resveratrol (Qiao et al., 2014), Berberine (Xie et al., 2011; Zhang
et al., 2012a), Quercetin (Etxeberria et al., 2015b)] and foods
[apple (Jiang et al., 2016; Masumoto et al., 2016), nopal (Sanchez-
Tapia et al., 2017), wheat (Kieffer et al., 2016), Laminarin (Nguyen
et al., 2016)], as well as in QHD (Feng et al., 2017) and berberine
(Cao et al., 2016) for NAFLD (Feng et al., 2017), and barley
for CVD (Wang Y. et al., 2016). All of these studies confirmed
that increase in gut bacteria phylum Bacteroidetes, and inhibition
of Firmicutes, and alteration of Firmicutes/Bacteroidetes ratio
helped to treat CMDs including obesity (Ley et al., 2006;
Sweeney and Morton, 2013), insulin resistance (Greenhill, 2015),
NAFLD (Liu J. P. et al., 2016) and CVD (Marques et al.,
2017). In addition, an increase in the Akkermansia population
was found to be in favorable treatment for T2D (Shin et al.,
2014), obesity (Everard et al., 2013), AS (Li J. et al., 2016)
and some other metabolic syndromes (Roopchand et al., 2015).
A recent study showed that fat mass development, insulin
resistance and dyslipidemia were reduced by purified membrane
protein from Akkermansia (Plovier et al., 2017). Interestingly,
the abundance of Akkermansia was dramatically increased not
only by Daesiho-tang for T2D (Hussain et al., 2016) and agave
salmiana for hepatic steatosis (Leal-Diaz et al., 2016), but also by
Flos Lonicera (Wang J. H. et al., 2014), pterostilbene (Etxeberria
et al., 2016), apple (Masumoto et al., 2016), grape (Baldwin
et al., 2016), agave salmiana (Leal-Diaz et al., 2016), cranberry
(Anhe et al., 2015), green tea (Liu Z. et al., 2016; Singh et al.,
2017), melatonine (Xu P. et al., 2017) and capsaicin (Kang et al.,
2017) for obesity. Moreover, various diseases such as obesity,
diabetes and ballergies have been associated with lower numbers
of Bifidobacterium at various stages of life (Arboleya et al.,
2016). The therapeutical effects of RS for AS (Chen M. L. et al.,
2016), berberine for NAFLD (Cao et al., 2016), and Rehmannia
glutinosa Libosch (Han et al., 2015), Daesiho-tang (Hussain et al.,
2016), rhein (Wang et al., 2016), tea polyphenols (Singh et al.,
2017), green tea (Singh et al., 2017) for obesity were associated
with the elevated abundance of Bifidobacterium. What’s more,
increased abundance of genus Lactobacillus, Bacteroides, and
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Prevotella which contribute to metabolic diseases and/or CVD,
were also closely associated with digestion of herbals and foods, as
shown in Tables 1–5. In summary, increasing the abundance of
phylum Bacteroidetes, and genus Akkermansia, Bifidobacterium,
Lactobacillus, Bacteroides, and Prevotella, while reducing phylum
Firmicutes and Firmicutes/Bacteroidetes ratio may serve as the
common characteristics for gut bacteria modulation of herbal
medicine and functional food for CMDs. For future studies,
the related gut microbiota species interplay with plants and
mammalian hosts need to be further investigated.
POTENTIAL EFFECTS OF HERBAL
MEDICINE AND FUNCTIONAL FOOD ON
GUT-ORGANS AXES
Commensal gut bacteria impact the host health especially
CMDs processes in multiple organs. Several new concepts
are proposed in recent reviews focusing on the relationship
between gut and organs, such as gut-heart axis (Buglioni and
Burnett, 2013), gut-brain axis (De Clercq et al., 2017; Dinan
and Cryan, 2017), gut-liver axis (Wiest et al., 2017), gut-kidney
axis (Katagiri et al., 2013; Budden et al., 2017) and gut-liver-
lung axis (Young et al., 2016). The gut is no longer viewed
as just a digestive organ, it is also considered as a metabolic
and immunomodulatory organ. The major components of fiber,
polyphenols and polysaccharides are present in large quantities
in both herbal medicine and functianl food, which we have
analyzed above. Besides, their muti-ingredient, muti-target and
muti-pathway mode are well known and capable of meeting
the complex system of the gut-organ interactions. Targetinig the
gut-organs axes may also be responsible for CMD treatment.
The potential effects are implicated by some latest reports.
For instance, a recently published study found that chronic
prebiotic treatment indeed exhibited both antidepressant and
anxiolytic effects, reduced stress-induced corticosterone release,
and modified specific gene expression in the hippocampus and
hypothalamus. These effects were exerted via increased cecal
acetate and propionate and reduced isobutyrate concentrations.
These findings provided clear evidence supporting therapeutic
targeting of the gut microbiota for gut-brain axis disorders
(Burokas et al., 2017). Another recent finding (Marques et al.,
2017) illustrated how HFD and supplementation with acetate
influenced gut-heart-kidney axis in a mouse hypertension and
heart failure model. It was found that both fiber and acetate
decreased gut dysbiosis, measured by the ratio of Firmicutes
to Bacteroidetes, and increased the prevalence of Bacteroides
acidifaciens. BothHFD and acetate supplementation significantly
reduced blood pressure, cardiac fibrosis, and left ventricular
hypertrophy. Transcriptome analyses showed that the protective
effects of high fiber and acetate were accompanied by the
downregulation of cardiac and renal early growth response
protein 1 (EGR1), a master cardiovascular regulator involved in
cardiac hypertrophy, cardiorenal fibrosis, and inflammation. The
upregulation of a network of genes involved in circadian rhythm
in both tissues and downregulation of the renin-angiotensin
system in the kidney and MAPK signaling in the heart presents
an interesting example of gut-multi organs interactions that are
simultaneously affected by diet via microbiota.
Althrough there are no reports on herbal medicine or
functional food directly targeting gut-organs axes, more study
should be carried out in the area to fully exploit the beneficial
aspects of gut microbiota. Major components such as fiber and
polysaccharide could be fermented and converted into SCFAs
which has been shown to be beneficial on the treatment of CMDs.
It is foreseeable that the influence of functional food and herbal
medicine on the interactive and dynamic relationships between
gut microbiota and essential organs will be elucidated in the
future.
CONCLUSIONS AND PERSPECTIVE
The concept of “medicine-food homology” has evolved from its
ancient origin and is given a new prospective with newly revealed
role of gut microbiota of the host. Human diseases, particularly
CMDs, not only could be treated by herbal derived medicine, but
also could be prevented by medicinal food via co-inhabiting and
influcing gut microbiota.
With the rapid advancement of sequencing technology and
intense efforts by researchers, a significant understanding of
host gut microbiota has been achieved (Xiao et al., 2017). It
is also becoming apparent that herbal medicine and functional
food may strongly influence gut microbiota associated with
CMDs in humans ranging from obesity to T2D and CVD.
Nevertheless, studies on the interaction between herbal derived
bioactive compounds and gut microbes are still needed. Future
investigation in the field may include, but not limited to
the following directions: (1) disease-related and disease-specific
microbiota and pathological mechanisms; (2) future research on
herbal medicine and functional food should exploit molecular
mechanisms and the relationship between microbiota and
host behavior; (3) until now, most medicine and functional
food research has focused on obesity and T2D rather than
CVD, which deserves more careful studies and funding;
(4) certain polyphenols (puerarin, paeoniflorin, baicalein,
icariin, mangiferin, gallic acid, luteolin, cryptotanshinone,
kaempferol, etc.) are similar to RSV and showed poor
absorption into the bloodstream after oral administration,
but they may have an impact on gut microbiota as well.
In conclusion (Figure 1), herbal medicine and functional
food with major ingredients including fiber, polyphenols
and polysaccharides are inclined to increasing abundance of
phylum Bacteroidetes, and genus Akkermansia, Bifidobacterium,
Lactobacillus, Bacteroides, and Prevotella, while reducing phylum
Firmicutes and Firmicutes/Bacteroidetes ratio to prevent or treat
CMDs through SCFAs, BAs, LPS and TMAO signaling. The
condition of health or disease in human is critically dependent
on the balance between medicine/food by modulating gut
microbiota. Human intake of herbal medicine and functional
food can alter gut microbiota, and microbiome in turn can
influce human health through microbial metabolites. The
convergence between herbal medicine and functional food
through microbiota reinforces the idea that CMDs are not
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FIGURE 1 | The potentially shared biological processes and underlying mechanisms of herbal medicine and functional food for CMDs through modulating microbiota.
only treatable but also preventable by maintaining the balance
between the two.
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